Of particular interest was the high frequency of FH-deficient tumors among leiomyomas with bizarre nuclei; although not an unambiguous indicator for HLRCC, the possibility of this highly penetrant tumor predisposition syndrome should be considered and additional suggestive clinical characteristics evaluated when these tumors are encountered at the clinic. The gene discussed is FH; the disease is hereditary leiomyomatosis and renal cell cancer.